Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer-Reference-Cited by-同舟云学术

Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer

Published:2016-02-12 Issue:2 Volume:2016 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Wulaningsih Wahyu¹²³,Wardhana Ardyan³⁴,Watkins Johnathan³⁵,Yoshuantari Naomi³⁶,Repana Dimitra⁷,Van Hemelrijck Mieke¹

Affiliation:

1. Faculty of Life Sciences and Medicine, King's College London; Cancer Epidemiology Group, Division of Studies; Research Oncology, 3rd floor Bermondsey Wing, Guy's Hospital London England UK SE1 9RT

2. Gadjah Mada University; Division of Haematology and Oncology, Department of Internal Medicine; Jalan Kesehatan No.1 Sekip Yogyakarta Yogyakarta Indonesia

3. PILAR Research and Education; CB1 Business Centre, 20 Station Road, Cambridge CB1 2JD United Kingdom Cambridge UK CB1 2JD

4. Faculty of Medicine, Gadjah Mada University; Department of Anesthesiology; Jl. Kesehatan 1, Sekip Yogyakarta Yogyakarta Indonesia

5. King's College London; Institute for Mathematics and Molecular Biomedicine; London UK SE1 1UL

6. Faculty of Medicine, Gadjah Mada University; Department of Cellular and Anatomic Pathology; Jalan Kesehatan No.1 Sekip Prof. Drs. Med. R. Radiopoetro Building 4th Floor Yogyakarta Daerah Istimewa Yogyakarta Indonesia 55284

7. Guy's and St Thomas' NHS Foundation Trust; Department of Medical Oncology; London UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference48 articles.

1. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients;Bécouarn;Journal of Clinical Oncology,2001

2. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected];Clarke;European Journal of Cancer,2011

3. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma;Graeven;Onkologie,2007

4. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group;Saltz;New England Journal of Medicine,2000

5. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial;Seymour;Lancet,2007

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanomedicine-based multimodal therapies: Recent progress and perspectives in colon cancer;World Journal of Gastroenterology;2023-01-28

2. Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer;Technology in Cancer Research & Treatment;2023-01

3. A novel irinotecan derivative ZBH-1207 with different anti-tumor mechanism from CPT-11 against colon cancer cells;Molecular Biology Reports;2022-06-29

4. Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients;Frontiers in Oncology;2022-06-01

5. Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer;Journal of Cancer Research and Clinical Oncology;2022-03-22